Lilly(Eli) & Co XNYS: LLY

Expensive Performer

762.95 -45.16 (-5.59%)

7.1M

XNYS Volume

XNYS 29 Jul, 2025 5:30 PM (EDT)

Regulatory Approval

Eli Lilly rises on Friday after EU regulator recommends approval of its Alzheimer's drug Kisunla See details

Lilly(Eli) & Co quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents